Climb Bio Inc
CLYM2.310USD
+0.070+3.12%
收盘 09/19, 16:00（美东）报价延迟15分钟
156.54M总市值
亏损市盈率 TTM
关于 Climb Bio Inc 公司
Climb Bio, Inc.（前身为 Eliem Therapeutics, Inc.）是一家临床阶段的生物技术公司。该公司专注于为患有免疫介导疾病的患者开发治疗方法。该公司的主要候选产品 budoprutug 是一种抗 CD19 单克隆抗体，旨在消耗 CD19 阳性 B 细胞（包括抗体分泌细胞），以直接减少致病性自身抗体。自身抗体的减少有可能改善自身抗体驱动疾病，例如系统性红斑狼疮、免疫性血小板减少症和膜性肾病。budoprutug 正处于 I 期临床试验阶段。
公司简介
公司代码CLYM
公司名称Climb Bio Inc
上市日期Aug 10, 2021
CEODr. Aoife M. Brennan
员工数量17
证券类型Ordinary Share
年结日Aug 10
公司地址20 William Street
城市WELLESLEY HILLS
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02481
电话18668572596
网址https://climbbio.com/
公司代码CLYM
上市日期Aug 10, 2021
CEODr. Aoife M. Brennan
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月19日 周二
更新时间: 8月19日 周二
持股股东
股东类型
持股股东
持股股东
占比
RA Capital Management, LP
46.37%
Pontifax Venture Capital
7.68%
Access Industries, Inc.
7.39%
Cantor Fitzgerald, L.P
3.69%
Citi Investment Research (US)
2.38%
其他
32.49%
持股股东
持股股东
占比
RA Capital Management, LP
46.37%
Pontifax Venture Capital
7.68%
Access Industries, Inc.
7.39%
Cantor Fitzgerald, L.P
3.69%
Citi Investment Research (US)
2.38%
其他
32.49%
股东类型
持股股东
占比
Venture Capital
54.05%
Hedge Fund
12.08%
Investment Advisor
11.12%
Corporation
7.39%
Research Firm
3.35%
Investment Advisor/Hedge Fund
1.18%
Individual Investor
0.81%
其他
10.02%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
169
62.56M
92.58%
-4.83M
2025Q1
169
68.90M
101.99%
-1.34M
2024Q4
155
67.64M
100.63%
-51.77K
2024Q3
127
63.79M
95.46%
+1.90M
2024Q2
91
59.36M
99.92%
+31.16M
2024Q1
87
26.17M
94.38%
-3.33M
2023Q4
91
26.16M
95.54%
-3.35M
2023Q3
92
25.94M
95.83%
-3.54M
2023Q2
93
25.92M
96.06%
-3.17M
2023Q1
92
25.90M
96.01%
-3.10M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RA Capital Management, LP
31.42M
46.49%
--
--
Mar 31, 2025
Pontifax Venture Capital
5.21M
7.7%
+5.21M
--
Mar 31, 2025
Access Industries, Inc.
5.01M
7.41%
--
--
Aug 14, 2024
Cantor Fitzgerald, L.P
2.00M
2.96%
+1.35M
+207.37%
Mar 31, 2025
Citi Investment Research (US)
1.85M
2.74%
+1.83M
+8039.18%
Mar 31, 2025
Affinity Asset Advisors LLC
1.50M
2.22%
+1.00M
+200.00%
Mar 31, 2025
The Vanguard Group, Inc.
1.50M
2.22%
-3.70K
-0.25%
Mar 31, 2025
Deep Track Capital LP
1.04M
1.54%
--
--
Mar 31, 2025
Kynam Capital Management LP
1.05M
1.55%
+500.00K
+91.41%
Mar 31, 2025
Tang Capital Management, LLC
1.00M
1.48%
+1.00M
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月6日 周三
更新时间: 8月6日 周三
机构名称
占比
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Neuroscience and Healthcare ETF
0%
iShares Russell 2000 Value ETF
0%
查看更多
ProShares Ultra Nasdaq Biotechnology
占比0.01%
iShares Biotechnology ETF
占比0.01%
Invesco Nasdaq Biotechnology ETF
占比0.01%
iShares Micro-Cap ETF
占比0.01%
Avantis US Small Cap Equity ETF
占比0%
iShares Russell 2000 Growth ETF
占比0%
Proshares Ultra Russell 2000
占比0%
ProShares UltraPro Russell2000
占比0%
iShares Neuroscience and Healthcare ETF
占比0%
iShares Russell 2000 Value ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
